NCT06145048 (VISUALIZE) is a Phase 2 clinical trial of VGT-309 in Lung Cancer, sponsored by Vergent Bioscience, Inc..

Who is sponsoring NCT06145048?

NCT06145048 is sponsored by Vergent Bioscience, Inc..

What drugs are being tested in NCT06145048?

Interventions in NCT06145048: VGT-309.

What condition does NCT06145048 study?

NCT06145048 studies Lung Cancer, Lung Metastases.

Is NCT06145048 still recruiting?

NCT06145048 is currently completed. Last updated 28 March 2025.

Last reviewed 2025-03-28 · How we verify

NCT06145048: VISUALIZE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Completed Phase 2 Last updated 28 March 2025

What this trial tests

Phase 2 trial testing VGT-309 in Lung Cancer in 89 participants. Completed in 20 February 2025.

Timeline

5 October 2023

Primary endpoint
31 October 2024

20 February 2025

Quick facts

Lead sponsor	Vergent Bioscience, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	89
Start date	5 October 2023
Primary completion	31 October 2024
Estimated completion	20 February 2025
Sites	6 locations across United States, Australia

Drugs / interventions tested

VGT-309 — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Lung Metastases — all drugs for Lung Metastases →

Sponsor

Vergent Bioscience, Inc. — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or Lung Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by protocol amendment if deemed necessary by the DSC to meet primary and/or secondary objectives.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Phase 2 Clinical Trial of VGT-309 for Intraoperative Molecular Imaging During Pulmonary Resection.
Bou-Samra P, Kennedy GT, Chang A, Guo E, et al · · 2025 · cited 8× · PMID 38823756 · DOI 10.1016/j.athoracsur.2024.05.019
Chemical probes for enzyme imaging: challenges in design, synthesis and biomedical applications.
Nguyen J, Zabijak M, Poręba M. · · 2025 · cited 3× · PMID 41221117 · DOI 10.1039/d5sc05683g
Transforming Cancer Diagnosis and Therapy Through Fluorescent Hydrogels: A Review.
Masaeli E, Srinivasan S, Rajabzadeh AR. · · 2026 · cited 1× · PMID 40905474 · DOI 10.1002/adhm.202502577
Identifying Molecular Probes for Fluorescence-Guided Surgery in Neuroblastoma: A Systematic Review.
Hennessy M, Neville JJ, Privitera L, Sedgwick A, et al · · 2025 · PMID 40426729 · DOI 10.3390/children12050550

Verify or expand the search:

Other trials of VGT-309

Trials testing the same drug.

NCT06034197 — Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy · EARLY_PHASE1 · terminated
NCT05400226 — Phase 2 Study of VGT-309 in Lung Cancer · Phase 2 · completed

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Vergent Bioscience, Inc. trials

Trials by the same sponsor.

NCT05400226 — Phase 2 Study of VGT-309 in Lung Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06145048 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vergent Bioscience, Inc.
Last refreshed: 28 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing